Benefits of Lowering Cholesterol Levels in Older Patients. Ann Intern Med. 2001;134:S4. doi: 10.7326/0003-4819-134-10-200105150-00003
Download citation file:
Published: Ann Intern Med. 2001;134(10):S4.
Coronary heart disease is a major cause of death in middle-aged and older adults. Several factors, including a high blood cholesterol level, can increase a person's risk for this type of heart disease. Various diet and drug treatments can help lower cholesterol and reduce the risk for heart disease. For example, drug treatments that lower blood cholesterol levels can prevent heart attacks and deaths from coronary heart disease in middle-aged adults. How well these drug treatments work in older adults has not been clear, however.
To see whether pravastatin, a drug that lowers cholesterol levels, is more or less effective in preventing heart disease in people 65 years of age or older compared with people 31 to 64 years of age.
The study included 3514 men and women 65 to 75 years of age and 5500 men and women 31 to 64 years of age. All had had a heart attack or severe chest pain from heart disease. Some participants had cholesterol levels that were in the normal range, but the average cholesterol level among participants was high.
The researchers randomly assigned participants to receive either 40 mg of pravastatin daily or placebo pills. The placebo looked like pravastatin but did not contain any active ingredients. Participants were then followed for 6 years.
Compared with placebo, pravastatin lowered cholesterol levels and prevented bad outcomes in both older and younger participants. For every 1000 older patients treated during the 6-year study, pravastatin prevented 45 deaths and 133 major coronary events, including heart attacks, strokes, severe chest pain episodes, and heart surgeries. For every 1000 younger patients, pravastatin prevented 22 deaths and 107 major coronary events over 6 years. Both older and younger participants were able to take pravastatin without frequent or severe side effects.
This study was originally designed to see whether pravastatin would help people 31 to 75 years of age who already had heart disease. The decision to see whether the benefits of pravastatin were similar in older and younger participants was made after the study was completed; the findings may be less reliable because the study was not primarily designed to answer this question.
Pravastatin prevents deaths and other major heart- and circulation-related problems in both older and younger people with known heart disease and average or high cholesterol levels. The potential benefits of treatment over 6 years are higher for older than for younger people, mainly because older people have greater risks for heart and circulation problems to begin with.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Geriatric Medicine, Dyslipidemia, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only